Saturday, April 26, 2025, Las Vegas, Nevada, 8:00 AM – 9:30 AM Pacific Time (11:00 AM – 12:30 PM Eastern Time)

Data + Perspectives: Clinical Investigators Discuss the Emerging Role of AKT Inhibitors in the Care of Patients with Prostate Cancer

A CME Satellite Symposium Held in Conjunction with the American Urological Association Annual Meeting 2025 (AUA2025)

Register for in-person Register for webcast

Location
The Venetian Convention and Expo Center
201 Sands Avenue
Las Vegas, Nevada
Hotel Phone: (702) 414-1000

Program Schedule — Pacific Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

Meeting Room
Venetian Ballroom J – Level 2

There is no registration fee for this event. For the in-person symposium in Las Vegas, preregistration is required as seating is limited.  
 
Faculty
Leonard G Gomella, MD
The Bernard W Godwin Professor
of Prostate Cancer
Chairman, Department of Urology
Senior Director, Clinical Affairs
Sidney Kimmel Cancer Center
Enterprise VP for Urology, Jefferson Health
Editor-in-Chief, Canadian Journal of Urology International
Thomas Jefferson University
Philadelphia, Pennsylvania

Evan Y Yu, MD
Section Head, Medical Oncology
Clinical Research Division
Fred Hutchinson Cancer Center
Medical Director, Clinical Research Support
Fred Hutchinson Cancer Research Consortium
Professor of Medicine
Division of Hematology and Oncology
Department of Medicine
University of Washington School of Medicine
Seattle, Washington

Moderator
Daniel George, MD
Eleanor Easley Distinguished Chair
Professor of Medicine, Surgery and Urology
Duke University School of Medicine
ACS Research Professor
Co-Lead, DCI Center for Prostate
and Urologic Cancers
Duke Cancer Institute
Durham, North Carolina




This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
Program Schedule — Pacific Time
7:30 AM – 8:00 AM — Registration and Breakfast
8:00 AM – 9:30 AM — Educational Meeting

MODULE 1: Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella

  • Current management paradigm for mHSPC; rationale for treatment intensification with secondary hormonal agents and/or chemotherapy in this setting
  • Long-term outcomes observed with contemporary treatment strategies for patients with mHSPC
  • Clinical, biological and practical factors guiding the selection of therapy for individual patients with mHSPC
  • Ongoing trials attempting to move strategies that have proven effective in metastatic castration-resistant prostate cancer (mCRPC), such as PARP inhibitors and novel radiopharmaceuticals, into the mHSPC setting

MODULE 2: Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu

  • Validated molecular biomarkers to aid in risk stratification and clinical decision-making in prostate cancer; current guideline-recommended approaches to biomarker evaluation
  • Frequency of PTEN deficiency in patients with prostate cancer
  • Role of PTEN deficiency in prostate tumor formation and progression
  • Clinicopathological features and long-term outcomes associated with PTEN deficiency in prostate cancer
  • Available methods to assess PTEN status; optimal timing and approach to PTEN testing
  • Biological justification for targeting the PI3K/AKT/mTOR pathway in prostate cancer, particularly in PTEN-deficient disease

MODULE 3: Emerging Role of AKT Inhibition in mHSPC — Dr George

  • Published findings from the Phase III IPATential150 trial evaluating the AKT inhibitor ipatasertib in combination with abiraterone/prednisolone for mCRPC; effect of PTEN status on outcomes
  • Pharmacologic similarities and differences between ipatasertib and capivasertib; implications for efficacy and tolerability
  • Design, eligibility criteria and emerging efficacy and safety results from the Phase III CAPItello-281 trial assessing capivasertib with abiraterone and androgen deprivation therapy (ADT) for patients with de novo mHSPC and PTEN deficiency
  • Potential implications of the positive results from CAPItello-281 for mHSPC management
  • Design, eligibility criteria and primary and secondary endpoints of the ongoing Phase III CAPItello-280 trial evaluating capivasertib in combination with docetaxel/ADT for patients with mCRPC; estimated completion date
  • Spectrum of toxicities associated with capivasertib; optimal mitigation and management

Target Audience
This activity has been designed to meet the educational needs of urologists, medical and radiation oncologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appreciate the incidence and clinical relevance of PTEN deficiency in prostate cancer, and understand the optimal method for assessing PTEN status in patients.
  • Evaluate emerging Phase III data with combined AKT and androgen biosynthesis inhibition for patients with metastatic hormone-sensitive prostate cancer and PTEN deficiency, and consider the potential role of this form of therapy in the current treatment algorithm.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with AKT inhibitors in preparation for their potential availability for patients with prostate cancer.
  • Recall the design of ongoing clinical trials evaluating novel AKT inhibitors in combination with standard therapies for metastatic prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantor.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Gomella — Advisory Committees: AstraZeneca Pharmaceuticals LP, Ferring Pharmaceuticals, Lantheus, Merck; Patents: Through Thomas Jefferson University. Dr Yu — Advisory Committees: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Johnson & Johnson Pharmaceuticals, Lantheus, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Oncternal Therapeutics, Tolmar; Contracted Research: Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Dendreon Pharmaceuticals Inc, Lantheus, Merck, Oncternal Therapeutics, Seagen Inc, Tyra Biosciences Inc.

MODERATOR — Dr George — Advisory Committees: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Cardinal Health, Novartis, Pfizer Inc; Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Exelixis Inc, Johnson & Johnson Pharmaceuticals, Merck, Novartis; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Corvus Pharmaceuticals, Exelixis Inc, Merck, Novartis, Pfizer Inc; Data and Safety Monitoring Boards/Committees: AstraZeneca Pharmaceuticals LP; Nonrelevant Financial Relationships: IDEOlogy Health, MJH Life Sciences, Targeted Oncology, UpToDate, UroToday.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.

The Venetian Convention and Expo Center
201 Sands Avenue
Las Vegas, NV 89109
Hotel Phone: (702) 414-1000

Meeting Room
Venetian Ballroom J – Level 2

Directions
The Venetian Convention and Expo Center is the main venue for the AUA Annual Meeting 2025.

This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

There is no registration fee for this event. For the in-person symposium in Las Vegas, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for AUA2025.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.